Sign In
Buy SEER
$1.86
-0.0100 (-0.535%)
At Close: Jun 03, 2026
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
07:01pm, Thursday, 29'th Feb 2024
Seer, Inc. (SEER) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.36 per share a year ago.
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
04:05pm, Thursday, 29'th Feb 2024
Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data
Seer to Participate in the TD Cowen 44th Annual Health Care Conference
04:05pm, Wednesday, 21'st Feb 2024
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery
08:00am, Tuesday, 06'th Feb 2024
Study led by Weill Cornell Medicine demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies
Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom Fisher
10:56am, Friday, 02'nd Feb 2024
After losing some value lately, a hammer chart pattern has been formed for Seer, Inc. (SEER), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revi
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
04:05pm, Thursday, 01'st Feb 2024
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wil
Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference
04:05pm, Thursday, 21'st Dec 2023
REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co
Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
09:00am, Friday, 10'th Nov 2023
REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company man
Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500
09:00am, Wednesday, 08'th Nov 2023
Seer technology receives recognition for excellence in the field of proteomics Seer technology receives recognition for excellence in the field of proteomics
Seer, Inc. (SEER) Q3 2023 Earnings Call Transcript
10:31pm, Tuesday, 07'th Nov 2023
Seer, Inc. (NASDAQ:SEER ) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Omid Farokhzad - President, CEO David Horn - CFO Conference Call Partici
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
09:02pm, Tuesday, 07'th Nov 2023
Seer, Inc. (SEER) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.38 per share a year ago.
Seer Reports Third Quarter 2023 Financial Results
04:05pm, Tuesday, 07'th Nov 2023
Expanded access to the Proteograph™ Product Suite through the Seer Technology Access Center, new distributors and a new Center of Excellence Expanded access to the Proteograph™ Product Suite throu
Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program
09:00am, Wednesday, 01'st Nov 2023
Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services Panome Bio adds deep, unbiased proteomics to their proprietary metabolom
Seer to Report Third Quarter 2023 Financial Results on November 7, 2023
04:05pm, Thursday, 19'th Oct 2023
REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report
7 Contrarian Stocks to Buy for the High-Stakes Gambler
08:10pm, Thursday, 28'th Sep 2023
With the major equity indices printing some lackluster performances recently, the concept of contrarian stocks to buy might hit a bit differently now. Basically, with so many ideas printing red ink �
